3
Gerresheimer recorded a jump in revenues and earnings due to the first-time consolidation of Bormioli Pharma, which was acquired in 2024.
Revenues in the first quarter of 2025 rose by 11.6% to €520.1 million (Q1 2024: €466.1 million), while adjusted EBITDA increased by 13.1% to €91.5 million (Q1 2024: €80.9 million). The organic development compared to the pro forma figures for the prior-year quarter reflects a shift in revenues in the syringe business and subdued demand for moulded glass especially from the cosmetics sector. In organic terms, revenues fell by 6.5%…